X

Trial Profile

Phase I Study of Safety and Pharmacokinetics of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Surufatinib (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Hutchison MediPharma

Most Recent Events

21 Mar 2016 Results were published in a Chi-Med media release.
09 Nov 2015 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
30 Oct 2015 Data will be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, according to a Hutchison MediPharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com